Summary This study concentrated on the influence of 2-chloroethylnitrosocarbamoyl-L-alanine (CNC-L-ala) linked to oestradiol (CNA-L-ala-E2) or dihydrotestosterone (CNC-L-ala-DHT) in position 17 of the respective steroid hormone on tumour growth and receptor kinetics of methylnitrosourea-induced rat mammary carcinoma. Both compounds almost completely arrested logarithmically growing mammary carcinoma of Sprague-Dawley rats: in the first week CNC-L-ala-E2 blocked the growth of these tumours by 92% compared to untreated control animals while, in animals treated with the physically equimolar mixture of CNC-L-ala and oestradiol (positive control), tumour growth was inhibited by 51% only. CNC-L-ala-DHT arrested the tumour growth in the first week by 95%, while the respective positive control (CNC-L-ala plus dihydrotestosterone) effected a growth inhibition of 71% compared to the untreated control. These results correlate well with the influence of both drugs on the cytosolic receptor content of sexual steroid hormones in the tumours. CNC-L-ala-E2 depleted the content of oestradiol receptors and kept it down for a week, while concomitantly the content of progesterone receptors increased considerably and that of androgen receptors showed a short-lived decrease. CNC-L-ala-DHT depleted androgen receptors as well as progesterone receptors. The content of androgen receptors remained low for a week, while that of progesterone receptors recovered within 8 days. The content of oestrogen receptors showed a moderate decrease.
The average survival time of women suffering from metastasising mammary carcinoma has been about 19 months for more than 40 years (Patel et al., 1986; Petru & Schmiihl, 1987) . None of the efforts made in mono-and combination chemotherapy have been able to improve this parameter. For this reason there is a basic need to find a more selective therapy, capable of eliminating cancer cells more specifically than conventional chemotherapy. The autochthonous rat mammary carcinoma, induced by methylnitrosourea (MNU), offers certain similarities to human premenopausal receptorpositive breast cancer and therefore seems to be suited for the preclinical evaluation of drugs against this type of cancer (Wilkinson et al., 1986) . The outlined strategy is based on the presence of sexual steroid hormone receptors in 65-87% (Eppenberger et al., 1979; Kimura, 1984; Longcope et al., 1980; Mohammed et al., 1986) of human cancers and in 85% (Ruzicka et al., 1980) of rat neoplasias. According to the concept of Druckrey and Raabe (1952) , an advantage in terms of better targeting and higher therapeutic ratio is to be obtained when a cytostatic agent binds more selectively to tumour than to normal cells. In this study we investigated the effects of the nitrosourea derivative 2-chloroethylnitrosocarbamoyl-L-alanine (CNC-L-ala) linked to oestradiol (E2) or dihydrotestosterone (DHT) in terms of antineoplastic activity as well as receptor kinetics in MNU-induced receptor positive rat mammary carcinoma.
Material and methods

Chemicals
Crystalline N-methyl-N-nitrosourea (MNU) was synthesised by Dr M. Wiessler (Institute of Toxicology and Chemotherapy, German Cancer Research Center, Heidelberg). MNU was dissolved at 1% in Sorensen buffer, pH6, and distilled water (20/80, v/v) Figure 1 . CNC-L-ala, CNC-L-ala-E2 and CNC-L-ala-DHT were dissolved at 5% in DMSO.
Animals and tumour induction Virgin female Sprague-Dawley (SD) rats (Institut fur Versuchtierkunde, Hannover, FRG) were induced with MNU and tumour bearing rats were treated as described by Berger et al. (1986) . The tumours were removed under slight ether anaesthesia, shock-frozen in liquid nitrogen and then stored at -60°C for later hormone receptor determination.
Determination of hormone receptors
The techniques were modified according to Agarwal (1983) , Tate and Jordan (1983) , Moudgil (1983) and Norris (1983 Correspondence: M.R. Berger. All solutions were prepared in the following buffer: Tris/HCI, pH 7.4, 40 mM, EDTA 1.5 mM, sodium azide 3 mM, dithiothreitol 5 mM, sodium molybdate 10 mM, methylphenylsulphonylfluoride 1 mm and glycerol 10%. The hormone analogues moxestrol, methyltrienolone and promegestone were purchased from New England Nuclear (Dreieich, FRG). The compounds were stored in ethanol under nitrogen at -20°C at a concentration of I tLM of the radioactive and 1 mM of the non-radioactive compounds. One mM triamcinolone acetonide, purchased from Sigma (Munich, FRG), was added to the radioactive methyltrienolone.
The frozen tumours were cooled in liquid nitrogen and pulverised with a ball mill (type Micro-Dismembrator II, Braun Melsungen, FRG). Two ml buffer was added to 1 g of tissue powder and the suspension was homogenised with 10 strokes in a Dounce homogeniser. The homogenate was centrifuged at 5,000 g for 5 min, the pellet was homogenised once more as before and the supernatants were collected. The combined supernatants were centrifuged at 100,000g for 1 h and the clear epiphase was taken for the cytosolic fraction. The extract was stored for maximally 3 days at -60°C.
The extract was diluted to 5 mg ml1' protein, as measured by the Bio-Rad protein assay (Bio-Rad Laboratories GmbH, Munich, FRG). Logarithmically decreasing concentrations of radioactive hormone (highest concentration 30 nM) in a volume of 0.1 ml were added to 0.1 ml extract and either 0.1 ml buffer or 0.1 ml non-radioactive hormone at 1,000-fold higher concentrations than the radioactive agent. After incubation for 2 h, 0.5 ml solution of 0.8% charcoal and 0.008% dextran 60 was added and incubated for 5 min. After centrifugation at 1,000 g for 5 min, 0.4 ml supernatant was taken and the radioactivity was measured with 4 ml Aqualuma (NEN, Dreieich, FRG) in a liquid scintillation counter (Mark III, Searle). All steps were performed in duplicate at + 4°C. volume per animal was calculated as the sum of all individual tumours. Therapeutic efficacy was measured on the basis of median total tumour volumes of treated groups vs controls (T/C x 100). Ranking criteria was chosen according to NCI recommendations. Statistical significance was based on 95% confidence limits of the median values per group. Additionally the tumour volumes of the groups were compared by using a non-parametric multivariate test according to Koziol and Donna (1981) . The survival times were compared according to the Kruskal-Wallis test (Dunn, 1964) .
For the graphical presentation of tumour growth the mean tumour volume was expressed as a resultant of the initial mean tumour volume plus the sum of the mean tumour volume changes between the respective time intervals.
The evaluation of the receptor content was performed according to the method of Scatchard (1949) .
Results
The compounds CNC-L-ala-E2 and CNC-L-ala-DHT clearly inhibited the growth of mammary tumours in SD rats induced by methylnitrosourea. Figures 3 and 4 and Table I show that the logarithmic growth of the tumours was less delayed by the physical mixture of the cytotoxic agent CNC-L-ala plus the respective hormone (positive control). Linking CNC-L-ala to oestradiol or dihydrotestosterone yielded a compound with stronger potency, probably also in comparison with the respective positive controls. The dihydrotestosterone derivative proved to be somewhat more active than that of oestradiol. After the end of therapy the advantage of the chemically linked derivatives was no longer detectable due to regrowth of tumours.
The influence of CNC-L-ala-E2 on the cytosolic receptor content of mammary tumours is shown in Figures 5-7 . There was a steep decrease of oestrogen receptors to barely detectable levels, which remained low for at least 4 days. The amount of progesterone receptors had increased more than twice after 48 h and then decreased to normal levels on day 8 after injection of the nitrosourea derivative. The content of androgen receptors had decreased after 48 h and partly replenished on day 8. The differential effect of CNC-L-ala-DHT on oestrogen, progesterone and androgen receptors is shown in androgen receptors for two days; partial replenishment could be detected on day 8 (Figure 8) . Interestingly, the content of progesterone receptors also decreased initially. The decrease, however, was not as steep as that of androgen receptors (Figure 9 ). From the minimum found after 24 h replenishment to normal levels occurred on day 8 after application of CNC-L-ala-DHT. The influence of this agent on oestradiol receptors is given in Figure 10 . A moderate decrease was seen 24 h after drug application, which reversed during the following 7 days. This work is part of a comprehensive stud) the pharmacokinetic and pharmacodynan steroid-linked cytotoxic drugs. In this article chemotherapeutic potential of CNC-L-ala-E2 and CNC-Lala-DHT as measured by their influence on tumour volume and the possible mechanism of action as indicated by their influence on measurable receptor contents in tumour cells. It was demonstrated that both linked compounds inhibited the growth of MNU-induced mammary carcinomas more than the unlinked positive controls, as expected according to the concept of Druckrey and Raabe (1952) . The differences observed (Figures 3 and 4) , however, were significant for CNC-L-ala-E2 only (P <0.02), and not for CNC-L-ala-DHT (P<0.1) ( Table I ). The relatively low number of treated animals, which was not sufficient to detect a significant advantage of the latter compound, is due to the fact that these groups belong to a comprehensive dose-response study, which was (Berger et al., 1986) and will be detailed elsewhere.
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Both conjugates exerted some prolongation of life span compared to untreated controls, which, however, was not tor content versus significant due to the regrowth of tumours following therapy. kg-' CNC-L-ala-
The toxicity of the linked compounds was significantly lower =Oh). The bars than that of the physical mixtures of CNC-L-ala and the respective hormone as indicated by the median survival times following administration of equimolar dosages (P = 0.03, P <0.01) (Berger et al., , 1986 Eisenbrand et al., 1988) .
This is in line with experiments on bone marrow toxicity in rats and mice: less suppression of bone marrow stem cell colony formation was observed following administration of the two linked agents compared to equimolar dosages of CNC-L-ala (Berger et al., 1985; Eisenbrand et al., 1989 ).
These results demonstrate the possible therapeutic advantage of linking a cytotoxic agent to a suitable carrier, here a I sexual steroid hormone.
The significantly altered pharmacodynamic activity of one of the steroid-linked nitrosoureas can mainly be explained by pharmacokinetic properties (Betsch et al., 1989) . In comparison with the unlinked single agent CNC-L-ala the conjugate to oestradiol showed a three times faster tissue distribution and a three-fold longer half-life in plasma (167 min).
In addition, the volume of distribution (2.36 litres kg-') of the oestradiol-linked drug was three times larger than that of receptor content CNC-L-ala, indicating a drug accumulation in certain body pmol kg-CNC-compartments. Disposition studies showed that the intact ction = 0 h). The oestradiol-linked drug could be detected in receptor containations.
ing normal (uterus) and tumour (mammary carcinoma) tissues at more than two times higher concentrations and over five-fold longer periods of time than CNC-L-ala (Betsch et al., 1990) . Compared to CNC-L-ala and its physical mixture with oestradiol, CNC-L-ala-E2 showed also superior activity against mammary carcinoma cells in vitro (Petru et al., 1988) . This is surprising because CNC-L-ala-E2 has a distinctly lower halflife in vitro (t, = 24 min in serum) than its parent drug CNC-L-ala (t1 = 62 min in serum) (Palm et al., 1989) . Studies on binding drugs to hormone receptors showed that the linked compounds have some affinity to the hormone receptors (up to 5% relative binding affinity of the respective hormone; Berger et al., 1986; Eisenbrand et al., 1989) . Crossaffinity from CNC-L-ala-DHT-17-ester to the progesterone receptor was also demonstrated (0.12%; Eisenbrand et al., 1989) . Determination of hormone receptor kinetics in this study show that the conjugates specifically influence the 150 200 receptors. The influence of CNC-L-ala-E2 on progesterone receptors resembles the physiological oestradiol influence (Chico et al., 1984; Katzenellenbogen, 1980) (Katzenellenbogen, 1980) .
Since the content of oestrogen receptors stayed low for at least 8 days, the second injection of CNC-L-ala-E2 to mammary carcinoma bearing rats was given to a tumour cell population with low receptor content (Figure 3 ). This may be the reason why the second application exhibited somewhat concerned with reduced anti-tumour efficacy. The effects of CNC-L-ala-DHT iic activities of on receptor contents, however, were partially reversible we describe the within 8 days and this may be the reason why the second application after 1 week prolonged the initially high anti-neoplastic activity (Figure 4) . The effects of CNC-L-ala-DHT in comparison to dihydrotestosterone were unphysiological to all three sexual steroid hormone receptors (Katzenellenbogen, 1980) . These results permit us to hypothesise that the better anti-tumour activity of CNC-Lala-DHT compared to the E2-conjugate results from its more severe disturbance of the physiological receptor kinetics. Considering these observations and the facts that no difference in anti-neoplastic activity between CNC-L-ala-E2 and the positive control was found in ovariectomised animals as well as that CNC-L-ala alone exerts no influence on steroid receptors (Berger et al., 1986) , the anti-neoplastic activity of the linked drugs probably was intensified by their interaction with hormone receptors and the intracellular effects thus originated. The affinity of the conjugates to the receptors is by about two orders of magnitude lower than that of the respective physiological hormones. Relatively high concentrations of the drugs are therefore needed to compete with physiological hormone concentrations. Although the toxicity of the linked compounds was lower than that of their positive controls, their therapeutic ratio is still moderate. Nevertheless, therapeutically active concentrations can be achieved in receptor-positive tumour tissue (Betsch et al., 1990) and reduced overall toxicity of the conjugates allows repeated administrations within a reasonable period of time; both properties represent discernible progress in the development of targeting molecules and of nitrosoureas with increased therapeutic ratio. Obviously, drugs with higher binding affinity to the hormone receptors are needed, which will allow further dose reduction due to more specific antineoplastic activity. Future studies will have to concentrate on conjugates in which the moderately active cytotoxic moiety CNC-L-ala (Klenner et al., 1989) has been replaced by more active principles and on suited combinations of hormonelinked cytotoxic agents, as well.
In summary, the data show that both linked compounds were superior to their unlinked positive controls and their efficacy was correlated with specific modulation of the receptor contents. Although the higher anti-neoplastic activity and lower toxicity observed resulted in higher therapeutic ratio, the resulting anti-cancer potency might further be improved by tailoring compounds with higher receptor affinity to the target cells.
